Over the past decade, the landscape of psoriasis treatment has been profoundly transformed by the introduction of biotechnological drugs, specifically monoclonal antibodies targeting the inflammatory pathways of IL-17 (Interleukin-17) and IL-23 (Interleukin-23) [1]. The gene discussed is IL17A; the disease is psoriasis.